CRIS Current Research Information System

IACOBUCCI, ILARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.099
EU - Europa 10.122
AS - Asia 5.119
AF - Africa 635
SA - Sud America 30
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 12
Totale 28.033
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.037
GB - Regno Unito 3.385
SE - Svezia 1.992
VN - Vietnam 1.624
CN - Cina 1.602
DE - Germania 1.250
IT - Italia 1.081
SG - Singapore 796
IN - India 630
IE - Irlanda 399
FR - Francia 377
RU - Federazione Russa 373
UA - Ucraina 345
ZA - Sudafrica 259
EE - Estonia 228
CH - Svizzera 192
TG - Togo 191
GR - Grecia 154
BG - Bulgaria 106
JO - Giordania 100
JP - Giappone 93
IR - Iran 85
FI - Finlandia 78
NG - Nigeria 74
CI - Costa d'Avorio 72
CA - Canada 59
BE - Belgio 55
TR - Turchia 37
KR - Corea 36
SC - Seychelles 33
NL - Olanda 24
PH - Filippine 23
AT - Austria 18
LB - Libano 18
BR - Brasile 17
PL - Polonia 17
CZ - Repubblica Ceca 15
AU - Australia 14
UZ - Uzbekistan 11
ES - Italia 10
EU - Europa 10
HK - Hong Kong 10
TW - Taiwan 9
ID - Indonesia 7
MY - Malesia 7
RO - Romania 7
BD - Bangladesh 6
CL - Cile 6
EG - Egitto 4
KZ - Kazakistan 4
PE - Perù 4
HR - Croazia 3
PK - Pakistan 3
RS - Serbia 3
SA - Arabia Saudita 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AR - Argentina 2
IQ - Iraq 2
MA - Marocco 2
NZ - Nuova Zelanda 2
PA - Panama 2
PT - Portogallo 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TM - Turkmenistan 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BS - Bahamas 1
IL - Israele 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
SY - Repubblica araba siriana 1
Totale 28.033
Salva come PNG Salva come JPEG
Città #
Southend 3.194
Fairfield 1.499
Chandler 1.347
Dong Ket 981
Ashburn 905
Houston 813
Wilmington 752
Woodbridge 720
Singapore 665
Seattle 640
Princeton 607
Ann Arbor 564
Cambridge 506
Dublin 398
Westminster 294
Nanjing 279
Padova 263
Beijing 246
Bologna 210
Lomé 191
Medford 169
Bern 164
Jacksonville 155
Jinan 147
Shenyang 138
Santa Clara 135
Saint Petersburg 134
Berlin 133
New York 131
Sofia 106
Hebei 105
Nanchang 104
Amman 100
San Diego 93
Changsha 90
Redmond 86
Boardman 82
Bremen 79
Falls Church 77
Helsinki 77
Abeokuta 74
Turin 74
Abidjan 72
Tokyo 71
Milan 63
Tianjin 60
Jiaxing 59
Florence 55
Brussels 53
Mülheim 51
Norwalk 50
Haikou 48
Redwood City 48
Zhengzhou 45
Los Angeles 39
Ningbo 37
Mountain View 36
Hangzhou 35
Istanbul 30
Mahé 30
Dearborn 29
Frankfurt am Main 29
Athens 28
Kunming 28
Taiyuan 28
Grafing 26
Guangzhou 26
Taizhou 26
Toronto 25
Olalla 24
North York 23
Davao City 21
Des Moines 21
Lanzhou 20
Rome 20
Tehran 19
Zanjan 19
Andover 17
Bühl 17
Hyderabad 17
Leawood 17
Paris 17
Pune 14
London 13
Phoenix 13
Vienna 12
Washington 12
Frankfurt Am Main 11
Fuzhou 11
Groningen 11
Orange 11
San Venanzo 11
São Paulo 11
Verona 11
Halethorpe 10
Ardabil 9
Faenza 9
Hong Kong 9
Las Vegas 9
Tappahannock 9
Totale 19.102
Salva come PNG Salva come JPEG
Nome #
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 275
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 269
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 248
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 230
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 225
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 218
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 215
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 212
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 210
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 197
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 195
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 193
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 190
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 187
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 187
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 175
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 175
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 171
A case report of acute myeloid leukemia and neurofibromatosis 1 168
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 161
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 159
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration 155
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 155
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 154
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 153
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 152
Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model 152
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 148
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 147
AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. 140
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. 140
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 139
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. 138
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 137
Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial 137
RALE051: a novel established cell line of sporadic Burkitt lymphoma 136
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 136
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 134
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 132
Choosing the Best Second-Line Tyrosine Kinase Inhibitor in Imatinib-Resistant Chronic Myeloid Leukemia Patients Harboring Bcr-Abl Kinase Domain Mutations: How Reliable Is the IC50? 131
Clec12a: A new AML stem cell-associated antigen 131
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 131
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 129
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 129
Inhibition of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) is a novel therapeutic strategy in B- and T-Acute Lymphoblastic Leukemia (ALL). 128
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 127
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 126
Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients 125
Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: A new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients 125
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 125
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 125
Association between transporters genotype and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the tops trial. 124
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 123
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 123
null 122
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 121
DEEP MOLECULAR CHARACTERIZATION OF ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BC-ALL) NEGATIVE FOR RECURRENT FUSION GENES REVEALS A HIGH COMPLEX GENETIC HETEROGENEITY INFLUENCING PROGNOSIS 121
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 121
Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. 119
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party 119
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 119
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 119
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 119
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 119
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 118
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 118
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 118
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL) 118
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. 117
Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy. 117
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 117
The cell cycle checkpoint inhibitors in the treatment of leukemias 117
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 117
Gas1 and Kif27 genes are strongly up-regulated biomarkers of Hedgehog inhibition (PF-04449913) on leukemia stem cells in Phase I Acute Myeloid Leukemia and Chronic Myeloid Leukemia treated patients 117
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 116
Pediatric-Like Intensified Therapy In Adult Acute Lymphoblastic Leukemia: A Single Centre Experience 116
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells. 115
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 115
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 115
GAS1 AND KIF27 GENES ARE STRONGLY UP-REGULATED BIOMARKERS OF HEDGEHOG INHIBITION (PF-04449913) ON LEUKEMIA STEM CELLS IN PHASE I ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOID LEUKEMIA TREATED PATIENTS 114
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia 114
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 113
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 110
COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES 109
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 108
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 108
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 107
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables 107
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 107
Monitoring minimal residual disease and controlling drug resistance in chronicmyeloid leukaemia patients in treatment with imatinib as a guide to clinicalmanagement. 106
Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression 106
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 106
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 106
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 106
Loss of Heterozygosity At the C Wild-Type Allele of rs1042522 in the TP53 Gene Frequently Occurs During Progression of Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) 105
SNP array reveals a new deletion of JAK2 in AML patients 105
Aurora kinase inhibitors: which role in the treatment of chronic myelogenous leukemia patients resistant to imatinib? 105
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 104
null 104
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 104
Totale 13.951
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.829
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.829
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20206.001 0 0 41 555 700 748 863 765 1.037 452 375 465
2020/20214.100 754 212 118 81 98 139 73 238 417 166 162 1.642
2021/20225.675 686 129 403 489 576 397 104 364 273 397 917 940
2022/20235.807 700 959 297 758 401 451 192 336 887 130 408 288
2023/20241.517 66 250 64 126 119 360 111 83 62 69 94 113
2024/20251.258 248 894 116 0 0 0 0 0 0 0 0 0
Totale 28.764